Principles of early drug discovery
暂无分享,去创建一个
[1] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[2] S. Rees,et al. Recombinant aequorin as reporter of changes in intracellular calcium in mammalian cells. , 2000, Methods in enzymology.
[3] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[4] K Moore,et al. Cell-Based Versus Isolated Target Screening: How Lucky Do You Feel? , 2001, Journal of biomolecular screening.
[5] Philip M Dean,et al. Probes for chemical genomics by design. , 2002, Drug discovery today.
[6] J. Wyatt,et al. Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats , 2002, PAIN.
[7] N. Peet. What constitutes target validation , 2003 .
[8] B. Ding,et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia , 2004, Journal of Medical Genetics.
[9] T. Magnuson,et al. Ablation of MEKK4 Kinase Activity Causes Neurulation and Skeletal Patterning Defects in the Mouse Embryo , 2005, Molecular and Cellular Biology.
[10] P. Anand,et al. Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain , 2005, Pain.
[11] Hussain Jafri,et al. An SCN9A channelopathy causes congenital inability to experience pain , 2006, Nature.
[12] Sandra Fox,et al. High-Throughput Screening: Update on Practices and Success , 2006, Journal of biomolecular screening.
[13] G. Ugolini,et al. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain , 2007, Proceedings of the National Academy of Sciences.
[14] Campbell McInnes,et al. Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.
[15] R. Tanzi,et al. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.
[16] Y. Iba,et al. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic , 2008, Proceedings of the National Academy of Sciences of the United States of America.
[17] Kiran Boppana,et al. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models. , 2009, European journal of medicinal chemistry.
[18] S. Rees,et al. Use of primary human cells in high-throughput screens. , 2009, Methods in molecular biology.
[19] Yongliang Yang,et al. Target discovery from data mining approaches. , 2009, Drug discovery today.
[20] Mark Whittaker,et al. The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..
[21] John J. Rossi,et al. The promises and pitfalls of RNA-interference-based therapeutics , 2009, Nature.
[22] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[23] J. Frearson,et al. HTS and hit finding in academia – from chemical genomics to drug discovery , 2009, Drug discovery today.
[24] Ted M. Lakowski,et al. Approaches to measuring the activities of protein arginine N-methyltransferases. , 2010, Analytical biochemistry.
[25] Elisa Michelini,et al. Cell-based assays: fuelling drug discovery , 2010, Analytical and bioanalytical chemistry.